Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Sihuan Pharmaceutical IPO Said to Seek $700 Million

Don't Miss Out —
Follow us on:

Sept. 21 (Bloomberg) -- Sihuan Pharmaceutical Holdings Group Ltd. plans to raise as much as $700 million in an initial public offering in Hong Kong, according to two people familiar with the deal.

Morgan Stanley and UBS AG are managing the sale, said the people, who declined to be identified because the information was private. Haikou, China-based Sihuan Pharmaceutical, which delisted from Singapore’s stock exchange in December, plans to start trading in Hong Kong in late October or early November, the people said.

Rachel Chan, a Sihuan spokeswoman in Hong Kong, declined to comment. Nick Footitt, a Hong Kong-based spokesman for Morgan Stanley, and Chris Cockerill, a UBS spokesman in Hong Kong, also declined to comment.

Sihuan supplies drugs to hospitals across China through a sales network which covers almost every province in the country, according to the company’s website. Its drugs are used for the cardio-cerebral vascular system and the nervous system, the website says.

At least two other medical companies from mainland China, where demands are rising for drugs and medical services, are seeking to list in Hong Kong. China Medical System Holdings Ltd. is seeking about HK$1 billion ($129 million) in its initial sale, according to the prospectus for the transaction. The Shenzhen-based provider of pharmaceutical services plans to start trading on Sept. 28, the prospectus said.

MicroPort Scientific Corp., which makes equipment for keyhole surgery, raised about HK$1.54 billion selling shares at the top of its offer range, two people with knowledge of the transaction said yesterday. The Shanghai-based producer of coronary stents plans to start trading on Sept. 24, according to its prospectus.

To contact the reporters on this story: Fox Hu in Hong Kong at fhu7@bloomberg.net.

To contact the editor responsible for this story: Daniel Hauck at dhauck1@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.